Results from three Phase II studies reported a two-year survival rate ranging from 30 to 42% in metastatic melanoma patients treated with ipilimumab (10 mg/kg).

Bristol-Myers Squibb Co and Medarex Inc announced updated survival results from follow-up extensions of three Phase II ipilimumab studies of patients with advanced metastatic melanoma (Stage III or IV). The two-year survival rate ranged from 29.8 to 41.8% in patients who received ipilimumab (10 mg/kg). The results are based on follow-up of up to 37.5 months (median follow-up ranging from 10.1 to 16.3 months) of the patient population from studies 008, 022 and 007 treated with 10 mg/kg of ipilimumab (induction and maintenance) and, specifically, showed: Two-year survival rate of 32.8% in patients who had progressed while on or after receiving standard treatment; two-year survival rate of …